相关实验视频

Updated: Jan 27, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

富含cAMP的细胞外囊泡可以改善肺高血压的结果

Aritra Bhadra¹, Frederic Bonnie¹, Jenny Hewes^1,2

¹Department of Pharmacology, Frederick P. Whiddon College of Medicine, University of South Alabama, Mobile, Alabama, United States.

American journal of physiology. Lung cellular and molecular physiology

|January 26, 2026

概括

携带循环腺单酸盐 (cAMP-EVs) 的细胞外囊泡在治疗肺高血压方面表现有前途. 这项研究表明cAMP-EVs通过增强内皮功能来改善大鼠模型的结果.

科学领域:

心血管生物学心血管生物学
细胞信号传递细胞信号传递
细胞外囊泡生物学细胞外囊泡生物学

背景情况:

含有循环腺单酸盐 (cAMP-EVs) 的细胞外囊泡 (EVs) 激活内皮细胞中的蛋白激酶A信号.
在生理和病理条件下cAMP-EVs的精确功能仍然在很大程度上没有特征.
肺高血压是一种严重的疾病,治疗选择有限.

研究的目的:

研究cAMP-EVs在低氧引起的肺高血压的老鼠模型中的治疗潜力.
阐明cAMP-EVs发挥其作用的潜在分子机制.
评估cAMP-EVs对内皮细胞功能和肺动脉重塑的影响.

主要方法:

在Sprague-Dawley大鼠中,缺氧诱导的肺高血压模型.
在低氧暴露的最后几天使用cAMP-EVs或控制EVs进行治疗.
评估血液动力学参数 (肺动脉加速时间,肺动脉喷射时间),富尔顿指数和动脉壁厚度.
测量蛋白质激酶A活性和内皮氧化合成酶酸化.
在正常和缺氧条件下对肺内皮细胞和肺动脉光滑肌细胞 (PASMCs) 的体外培养研究.

主要成果:

用cAMP-EVs治疗显著改善了血液动力学参数,并降低了缺氧大鼠的富尔顿指数.
在肺组织中,CAMP-EVs增加了蛋白激酶A活性和内皮氧化合成酶酸化.
在体外,cAMP-EVs在低氧条件下抑制了PASMC的增殖.
对焦显微镜证实了EVs在肺组织中的吸收.

结论:

像cAMP这样的第二信使分子,当包装在EV中时,可以改善诸如肺高血压等病理状况.
在肺高血压的临床前模型中,CAMP-EV证明了治疗效果,可能是通过内皮依赖机制.
这些发现扩大了对肺循环中cAMP信号传递的理解,并提出了新的治疗策略.

关键词:

循环的腺单酸盐.细胞外囊泡细胞外囊泡肺内皮的肺内皮.肺高血压是一种肺高血压.右心室缩过高的情况

更多相关视频

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

An Enrichment Method for Small Extracellular Vesicles Derived from Liver Cancer Tissue

An Enrichment Method for Small Extracellular Vesicles Derived from Liver Cancer Tissue

Published on: February 3, 2023

相关概念视频

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...